Clinical Trial Update: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) [Phase 2, Phase 3]

View source ↗

Summary

FRUSICA-2 is evaluating the combination of Fruquintinib and Sintilimab in advanced renal cell carcinoma, currently in Phase 2/Phase 3 with status not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Hutchmed | Conditions: Advanced Renal Cell Carcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING